XTX Topco Ltd Has $152,000 Stake in Health Catalyst, Inc. (NASDAQ:HCAT)

XTX Topco Ltd reduced its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 34.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,727 shares of the company’s stock after selling 9,693 shares during the quarter. XTX Topco Ltd’s holdings in Health Catalyst were worth $152,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. First Light Asset Management LLC raised its holdings in shares of Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the period. Millennium Management LLC raised its stake in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares during the period. Nepsis Inc. lifted its position in shares of Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after buying an additional 851,448 shares during the last quarter. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst in the third quarter valued at approximately $6,858,000. Finally, Portolan Capital Management LLC bought a new position in shares of Health Catalyst during the 3rd quarter worth approximately $5,402,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on HCAT. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. JPMorgan Chase & Co. raised their target price on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Citigroup lifted their target price on shares of Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price target (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Finally, Royal Bank of Canada boosted their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.79.

Health Catalyst Trading Up 1.7 %

Shares of HCAT stock opened at $7.09 on Friday. The stock has a market cap of $431.41 million, a P/E ratio of -5.25 and a beta of 1.31. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock has a 50 day simple moving average of $8.11 and a 200 day simple moving average of $7.45.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.22) earnings per share. On average, research analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $7.88, for a total transaction of $50,762.96. Following the completion of the sale, the insider now directly owns 98,702 shares in the company, valued at $777,771.76. This represents a 6.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the completion of the transaction, the chief operating officer now owns 129,690 shares in the company, valued at approximately $998,613. The trade was a 3.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,551 shares of company stock worth $532,105 over the last ninety days. Corporate insiders own 2.50% of the company’s stock.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.